Anti-inflammatory and analgesic compound drug for reducing side effects of rofecoxib and application thereof

An anti-inflammatory analgesic and rofecoxib technology, applied in the field of compound drugs, can solve the problems of increasing the risk of heart disease or stroke, procoagulation, etc., to avoid myocardial infarction and stroke, and reduce the effect of abnormal coagulation function

Active Publication Date: 2017-05-03
罗国安
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in 2004, it was found that rofecoxib may increase the risk of heart disease or stroke, which was voluntarily recalled by Merck. Subsequent studies found that the main reason for the side effects of rofecoxib (vioxx) is that it may produce procoagulant effect, leading to cardiovascular disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-inflammatory and analgesic compound drug for reducing side effects of rofecoxib and application thereof
  • Anti-inflammatory and analgesic compound drug for reducing side effects of rofecoxib and application thereof
  • Anti-inflammatory and analgesic compound drug for reducing side effects of rofecoxib and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] An anti-inflammatory and analgesic compound medicine for reducing side effects of rofecoxib, comprising rofecoxib and notoginsenoside R1, the weight ratio of rofecoxib and notoginsenoside R1 is 1:1.

[0023] This drug was used in clinical trials, 79 of the 100 patients had obvious effects, and 50 of the 100 patients were cardiovascular and cerebrovascular patients, and the 50 patients with cardiovascular and cerebrovascular diseases did not aggravate after using this drug. In 29 of the other 50 non-cardiovascular patients, the probability of coagulation was reduced compared with rofecoxib alone after using this drug.

Embodiment 2

[0025] The anti-inflammatory and analgesic compound medicine for reducing the side effect of rofecoxib is composed of rofecoxib and aspirin, and the weight ratio of rofecoxib and aspirin is 1:1.

[0026] This drug was used in clinical trials, 84 of the 100 patients had obvious effects, and 50 of the 100 patients were cardiovascular and cerebrovascular patients, and 50 patients with cardiovascular and cerebrovascular diseases did not aggravate after using this drug. In addition, 34 of the other 50 non-cardiovascular patients had reduced the probability of coagulation after using this drug compared with rofecoxib alone.

Embodiment 3

[0028] An anti-inflammatory and analgesic compound drug for reducing the side effects of rofecoxib, consisting of rofecoxib, notoginsenoside R1 and aspirin, the weight ratio of rofecoxib, notoginsenoside R1 and aspirin is 2:1: 1. The notoginseng saponin R1 is isolated from Radix Notoginseng;

[0029] This drug was used in clinical trials, 88 of the 100 patients had obvious effects, and 50 of the 100 patients were cardiovascular and cerebrovascular patients, and 50 patients with cardiovascular and cerebrovascular diseases did not aggravate after using this drug. In addition, 38 of the other 50 non-cardiovascular patients had reduced the probability of coagulation after using this drug compared with rofecoxib alone.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of compound medicines, and in particular relates to a compound medicine composed of rofecoxib and the like. The compound medicine is composed of the rofecoxib and notoginsenoside R1 according to a ratio of 1 to (0.1-1), wherein the notoginsenoside R1 is extracted from panax pseudoginseng. The compound medicine can be composed of the rofecoxib and aspirin according to a ratio of 1 to (0.1-1). The compound medicine can also be composed of the rofecoxib, the notoginsenoside R1 and the aspirin according to a ratio of 2 to (0.1-1) to (0.1-1). The compound medicine obtained by compounding the rofecoxib can be used for lowering abnormal blood coagulation caused by the single application of the rofecoxib so as to avoid serious side effects such as myocardial infarction and apoplexy from being possibly generated.

Description

technical field [0001] The invention belongs to the field of compound medicines, in particular to a compound medicine composed of rofecoxib and the like. Background technique [0002] Rofecoxib (vioxx) is an oral specific cyclooxygenase COX-2 inhibitor approved by the US FDA in 1999 for the relief of osteoarthritis and rheumatoid arthritis, acute pain, and migraine and menstrual disorders. The selective inhibitor of COX-2 avoids the common gastrointestinal adverse reactions of traditional NSAIDs, so it was once hailed as the ace drug at the beginning of the market. However, in 2004, it was found that rofecoxib may increase the risk of heart disease or stroke, which was voluntarily recalled by Merck. Subsequent studies found that the main reason for the side effects of rofecoxib (vioxx) is that it may produce procoagulant effect, leading to cardiovascular disease. In 2010, a PNAS report stated that the procoagulant effect of rofecoxib was due to the accumulation of 20-HETE...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/704A61K31/616A61P29/00A61K31/341
Inventor 罗国安王义明
Owner 罗国安
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap